Academic Journal
Προβολή σε EDS

Anticancer drug-induced interstitial lung disease: a critical appraisal of clinical practice guidelines and consensus statements.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Anticancer drug-induced interstitial lung disease: a critical appraisal of clinical practice guidelines and consensus statements.
Συγγραφείς: Zhang Y; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.; Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China., Ma Z; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Sun X; Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing, China., Zhang Y; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Zhu M; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Zhang S; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China., Feng X; Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China., An Z; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Πηγή: Expert opinion on drug safety [Expert Opin Drug Saf] 2026 Jun; Vol. 25 (6), pp. 1093-1101. Date of Electronic Publication: 2024 Feb 20.
Τύπος έκδοσης: Journal Article; Review
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE
Imprint Name(s): Publication: 2015- : Abingdon, Oxford : Taylor & Francis
Original Publication: London : Ashley Publications, c2002-
Ιατρικοί όροι (MeSH): Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/administration & dosage , Lung Diseases, Interstitial*/chemically induced , Practice Guidelines as Topic*/standards , Consensus Statements as Topic*, Biomarkers/metabolism ; Steroids/administration & dosage ; Humans
Περίληψη: Anticancer drug-induced interstitial lung disease (DIILD) has received increasing clinical attention, and the quality of relevant guidance documents has become critical. Our purpose was to assess the quality of documents for anticancer DIILD and summarize the recommendations. Clinical practice guidelines (CPGs) and consensus statements with recommendations were searched in electronic databases, websites of guideline organizations, and professional societies. The quality of documents was assessed using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) methodology, and the specific recommendations were aggregated and compared. A total of 11 documents were eligible, including 6 CPGs and 5 consensus statements, and the quality of AGREE II assessments differed greatly. The domains of scope and purpose and clarity of presentation received the highest median scores, while the stakeholder involvement domain received the lowest score. Recommendations were inconsistent between documents, particularly regarding the selection of steroid regimens. The methodological quality of the guidance documents needs to be enhanced, especially in the domain of stakeholder involvement. Inconsistencies exist in documents, and further discussions among multidisciplinary experts are needed. Particularly, differences in steroid regimens require attentions, and researches on the risks of adverse events and discovery of precise biomarkers are necessary.
Contributed Indexing: Keywords: AGREE II; Anticancer drug; clinical practice guideline; consensus statement; interstitial lung disease; pneumonitis
Substance Nomenclature: 0 (Antineoplastic Agents)
0 (Biomarkers)
0 (Steroids)
Entry Date(s): Date Created: 20240207 Date Completed: 20260601 Latest Revision: 20260602
Update Code: 20260602
DOI: 10.1080/14740338.2024.2315113
PMID: 38323333
Βάση Δεδομένων: MEDLINE
FullText Text:
  Availability: 0
Header DbId: cmedm
DbLabel: MEDLINE
An: 38323333
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Anticancer drug-induced interstitial lung disease: a critical appraisal of clinical practice guidelines and consensus statements.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.; Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Ma+Z%22">Ma Z</searchLink>; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Sun+X%22">Sun X</searchLink>; Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Zhu+M%22">Zhu M</searchLink>; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Zhang+S%22">Zhang S</searchLink>; Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Feng+X%22">Feng X</searchLink>; Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.<br /><searchLink fieldCode="AU" term="%22An+Z%22">An Z</searchLink>; Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101163027%22">Expert opinion on drug safety</searchLink> [Expert Opin Drug Saf] 2026 Jun; Vol. 25 (6), pp. 1093-1101. <i>Date of Electronic Publication: </i>2024 Feb 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101163027 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-764X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214740338%22">14740338 </searchLink><i>NLM ISO Abbreviation: </i>Expert Opin Drug Saf <i>Subsets: </i>MEDLINE
– Name: PublisherInfo
  Label: Imprint Name(s)
  Group: PubInfo
  Data: <i>Publication</i>: 2015- : Abingdon, Oxford : Taylor & Francis<br /><i>Original Publication</i>: London : Ashley Publications, c2002-
– Name: SubjectMESH
  Label: MeSH Terms
  Group: Su
  Data: <searchLink fieldCode="MM" term="%22Antineoplastic+Agents%22">Antineoplastic Agents*</searchLink>/<searchLink fieldCode="MM" term="%22Antineoplastic+Agents+adverse+effects%22">adverse effects</searchLink> <br /><searchLink fieldCode="MM" term="%22Antineoplastic+Agents%22">Antineoplastic Agents*</searchLink>/<searchLink fieldCode="MM" term="%22Antineoplastic+Agents+administration+%26+dosage%22">administration & dosage</searchLink> <br /><searchLink fieldCode="MM" term="%22Lung+Diseases%2C+Interstitial%22">Lung Diseases, Interstitial*</searchLink>/<searchLink fieldCode="MM" term="%22Lung+Diseases%2C+Interstitial+chemically+induced%22">chemically induced</searchLink> <br /><searchLink fieldCode="MM" term="%22Practice+Guidelines+as+Topic%22">Practice Guidelines as Topic*</searchLink>/<searchLink fieldCode="MM" term="%22Practice+Guidelines+as+Topic+standards%22">standards</searchLink> <br /><searchLink fieldCode="MM" term="%22Consensus+Statements+as+Topic%22">Consensus Statements as Topic*</searchLink><br /><searchLink fieldCode="MH" term="%22Biomarkers%22">Biomarkers</searchLink>/<searchLink fieldCode="MH" term="%22Biomarkers+metabolism%22">metabolism</searchLink> ; <searchLink fieldCode="MH" term="%22Steroids%22">Steroids</searchLink>/<searchLink fieldCode="MH" term="%22Steroids+administration+%26+dosage%22">administration & dosage</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Anticancer drug-induced interstitial lung disease (DIILD) has received increasing clinical attention, and the quality of relevant guidance documents has become critical. Our purpose was to assess the quality of documents for anticancer DIILD and summarize the recommendations. Clinical practice guidelines (CPGs) and consensus statements with recommendations were searched in electronic databases, websites of guideline organizations, and professional societies. The quality of documents was assessed using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) methodology, and the specific recommendations were aggregated and compared. A total of 11 documents were eligible, including 6 CPGs and 5 consensus statements, and the quality of AGREE II assessments differed greatly. The domains of scope and purpose and clarity of presentation received the highest median scores, while the stakeholder involvement domain received the lowest score. Recommendations were inconsistent between documents, particularly regarding the selection of steroid regimens. The methodological quality of the guidance documents needs to be enhanced, especially in the domain of stakeholder involvement. Inconsistencies exist in documents, and further discussions among multidisciplinary experts are needed. Particularly, differences in steroid regimens require attentions, and researches on the risks of adverse events and discovery of precise biomarkers are necessary.
– Name: SubjectMinor
  Label: Contributed Indexing
  Group:
  Data: <i>Keywords: </i>AGREE II; Anticancer drug; clinical practice guideline; consensus statement; interstitial lung disease; pneumonitis
– Name: NumberCAS
  Label: Substance Nomenclature
  Group: ID
  Data: 0 (Antineoplastic Agents)<br />0 (Biomarkers)<br />0 (Steroids)
– Name: DateEntry
  Label: Entry Date(s)
  Group: Date
  Data: <i>Date Created: </i>20240207 <i>Date Completed: </i>20260601 <i>Latest Revision: </i>20260602
– Name: DateUpdate
  Label: Update Code
  Group: Date
  Data: 20260602
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1080/14740338.2024.2315113
– Name: AN
  Label: PMID
  Group: ID
  Data: 38323333
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=38323333
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14740338.2024.2315113
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1093
    Subjects:
      – SubjectFull: Biomarkers metabolism
        Type: general
      – SubjectFull: Steroids administration & dosage
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Antineoplastic Agents adverse effects
        Type: general
      – SubjectFull: Antineoplastic Agents administration & dosage
        Type: general
      – SubjectFull: Lung Diseases, Interstitial chemically induced
        Type: general
      – SubjectFull: Practice Guidelines as Topic standards
        Type: general
      – SubjectFull: Consensus Statements as Topic
        Type: general
    Titles:
      – TitleFull: Anticancer drug-induced interstitial lung disease: a critical appraisal of clinical practice guidelines and consensus statements.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: Ma Z
      – PersonEntity:
          Name:
            NameFull: Sun X
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: Zhu M
      – PersonEntity:
          Name:
            NameFull: Zhang S
      – PersonEntity:
          Name:
            NameFull: Feng X
      – PersonEntity:
          Name:
            NameFull: An Z
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1744-764X
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Expert opinion on drug safety
              Type: main
ResultId 1